Latest news with #MDT
Filipino Times
33 minutes ago
- Politics
- Filipino Times
Trump to Visit Manila for 2026 ASEAN Summit
United States President Donald Trump has confirmed his attendance at the 44th ASEAN Summit to be hosted by the Philippines in 2026, Philippine Ambassador to the U.S. Jose Manuel Romualdez revealed in an interview with NewsWatch Plus. The commitment came during a conversation between the two following an official luncheon held in Washington as part of President Ferdinand Marcos Jr.'s recent visit to the United States. Romualdez recalled asking Trump directly if he would attend the summit in Manila. 'Yes, I will definitely go,' Trump reportedly replied, according to the ambassador. Trump had previously stated in the Oval Office during a media engagement, 'If I'm invited, I'll go.' President Marcos formally extended the invitation, solidifying expectations that Trump will visit the country as part of the summit. The Philippines is set to host the 44th ASEAN Summit in 2026, which will coincide with two major milestones in PH-U.S. relations—the 80th anniversary of diplomatic ties and the 75th year of the Mutual Defense Treaty (MDT). The high-level summit will serve as a platform to strengthen regional cooperation and reaffirm longstanding alliances among member states and key partners like the United States. In his arrival statement from Washington, President Marcos described Trump's anticipated visit as a 'reaffirmation of our historic alliance.' He emphasized the importance of U.S.-Philippine relations, noting that the Mutual Defense Treaty remains a key pillar of the country's security framework. 'The United States is our oldest and only treaty ally,' Marcos said. 'This visit and summit will mark another chapter in our shared strategic interests.' Ask ChatGPT
Yahoo
3 hours ago
- Business
- Yahoo
Here's What to Expect From Medtronic's Next Earnings Report
Galway, Ireland-based Medtronic plc (MDT) designs, manufactures, and distributes a wide range of medical devices, therapies, and digital health solutions used to treat chronic and complex health conditions across global healthcare systems. Valued at a market cap of $118 billion, the company is committed to advancing medical technology to alleviate pain, restore health, and extend life. It is scheduled to announce its fiscal Q1 earnings for 2026 before the market opens on Tuesday, Aug. 19. Before this event, analysts project this healthcare giant to report a profit of $1.23 per share, in line with the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in each of the last four quarters. Its earnings of $1.62 per share in the previous quarter outpaced the consensus estimates by 2.5%. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For the full year, analysts expect MDT to report EPS of $5.55, up 1.1% from $5.49 per share in fiscal 2025. Furthermore, its EPS is expected to grow 7.9% year-over-year to $5.99 in fiscal 2027. MDT has rallied 15.9% over the past 52 weeks, outpacing both the S&P 500 Index's ($SPX) 14.5% uptick and the Health Care Select Sector SPDR Fund's (XLV) 8.3% drop over the same time frame. Despite delivering stronger-than-expected results, shares of Medtronic plunged 2.3% after its Q4 earnings release on May 21. The company's revenue improved 3.9% year-over-year to $8.9 billion, topping consensus estimates by 1.1%. Moreover, its adjusted EPS of $1.62 advanced nearly 11% from the year-ago quarter and came in 2.5% above the analyst expectations. Looking ahead to fiscal 2026, Medtronic expects adjusted EPS in the range of $5.50 to $5.60, and anticipates organic sales growth of approximately 5%. Wall Street analysts are moderately optimistic about MDT's stock, with an overall "Moderate Buy" rating. Among 30 analysts covering the stock, 13 recommend "Strong Buy," one indicates a "Moderate Buy," 15 advise 'Hold,' and one suggests a "Strong Sell' rating. The mean price target for Medtronic is $95.83, implying a 4.2% premium from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Medtronic's (MDT) Role in Medical Devices: A Unique Fit for Halal Portfolios
Medtronic plc (NYSE:MDT) is included among the 11 Best Halal Dividend Stocks to Buy Now. A surgeon in a modern operating room holding advanced medical devices with a sense of purpose and accuracy. Medtronic plc (NYSE:MDT) has maintained steady revenue and earnings over the years, demonstrating a track record of reliable performance. The company appears well-positioned to continue generating solid returns over time. This confidence stems from its strong innovation capabilities, established presence in the complex healthcare industry, and favorable long-term trends such as the global rise in aging populations. In fiscal Q4 2024, Medtronic plc (NYSE:MDT) reported revenue of $8.93 billion, which showed a 4% growth from the same period last year. The revenue also beat analysts' estimates by $98.2 million. The company posted a GAAP operating profit of $1.436 billion and an operating margin of 16.1%, reflecting year-over-year increases of 36% and 380 basis points, respectively. Medtronic plc (NYSE:MDT)'s cash position remained stable in FY25. The company's operating cash flow for the year was $7 billion, and its free cash flow amounted to $5.2 billion. It ended the year with $2.2 billion available in cash and cash equivalents. The company offers a quarterly dividend of $0.71 per share, having raised it by 1.4% in May. This marked the company's 48th consecutive year of dividend growth, which makes it one of the best halal stocks that pay dividends. As of July 18, the stock has a dividend yield of 3.17%. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
2 days ago
- Business
- Yahoo
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Medtronic (MDT) was up +2.17% at $91.65. This move outpaced the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.41%, and the Nasdaq, a tech-heavy index, lost 0.39%. The stock of medical device company has risen by 4.35% in the past month, leading the Medical sector's loss of 1.83% and undershooting the S&P 500's gain of 5.88%. The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on August 19, 2025. In that report, analysts expect Medtronic to post earnings of $1.23 per share. This would mark no growth from the year-ago period. Alongside, our most recent consensus estimate is anticipating revenue of $8.37 billion, indicating a 5.73% upward movement from the same quarter last year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $5.55 per share and a revenue of $35.29 billion, indicating changes of +1.09% and +5.22%, respectively, from the former year. It is also important to note the recent changes to analyst estimates for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% lower. Medtronic is currently a Zacks Rank #4 (Sell). From a valuation perspective, Medtronic is currently exchanging hands at a Forward P/E ratio of 16.17. Its industry sports an average Forward P/E of 18.47, so one might conclude that Medtronic is trading at a discount comparatively. It is also worth noting that MDT currently has a PEG ratio of 2.33. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.22. The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 177, which puts it in the bottom 29% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
New Straits Times
2 days ago
- Entertainment
- New Straits Times
#SHOWBIZ: 'The Saga of Taj Theatre' combines classical dance and comedy
KUALA LUMPUR: Mahavidya Dance Theatre (MDT) is set to return to the stage with 'The Saga of Taj Theatre', a captivating multi-genre performance. This unique production seamlessly blends Bharatanatyam, comedy theatre, and film projection into a single, compelling experience. The show will be staged at the Damansara Performing Arts Centre (DPAC) on July 26 and 27. This original production tells the story of an old theatre on the brink of demolition – a symbolic setting where the past and future dramatically collide. As the narrative unfolds, the performance beautifully incorporates a vibrant dance drama dedicated to Lord Brahma, a deity long associated with creation in Indian cultural tradition. To ensure a deeper audience connection, all dances are fully subtitled in English, and the innovative use of multimedia projections provides an accessible and visually rich storytelling experience. More than 20 performers will take to the stage in this grand production. The choreography and music are the result of a collaboration between award-winning artists from Malaysia and India, drawing from ancient South Indian classical traditions. Percussion arrangements are by Maestro Kalaimamani S. Gopakumar, with lyrics penned by Nirmala Raghavan. MDT founder Sheela Raghavan-Tan is responsible for the dance research and choreography. MDT operates as a non-profit dance school, offering free performing arts training to children from all backgrounds. Proceeds from 'The Saga of Taj Theatre' will directly support the expansion of these outreach programmes and help create more platforms for young, aspiring performers. Tickets for both the 5pm and 8pm shows are by donation.
